neoadjuvant anti-PD-1
Phase 2Small molecule
neoadjuvant anti-PD-1 is one of 91 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Esophageal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Beyfortus
BeiGenePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for neoadjuvant anti-PD-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Chest Hospital